NEW YORK (GenomeWeb News) – Nuvera Biosciences has licensed pharmacogenomic assays that it has developed to Veridex, which will commercialize the tests.

The multi-gene assays were developed for predicting patient response to tamoxifen therapy and taxane-containing chemotherapy in breast cancer. Woburn, Mass.-based Nuvera developed the assays in collaboration with the University of Texas MD Anderson Cancer Center.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: dynamics of protein profusion and localization, melanoma classification schemes, and more.

A company says it can generate likenesses of people based on their genetic profiles.

IBM's Watson is learning how to treat leukemia as a fellow at the MD Anderson Cancer Center, according to the Washington Post.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.